Trial Profile
Real-life data from the french temporary authorization for use (TAU) at the Institut de Cancérologie de l'Ouest to evaluate efficacy of palbociclib plus fulvestrant in advanced Hormone Receptor- positive (HR 1 ) metastatic breast cancer (MBC) pretreated with everolimus
Status:
Active, no longer recruiting
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 11 Jan 2018
Price :
$35
*
At a glance
- Drugs Fulvestrant (Primary) ; Palbociclib (Primary)
- Indications Advanced breast cancer
- Focus Expanded access; Therapeutic Use
- 09 Dec 2017 Results assessing efficacy presented at the 40th Annual San Antonio Breast Cancer Symposium
- 13 Oct 2017 New trial record
- 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress